

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)



(10) International Publication Number
WO 2022/129953 A1

(51) International Patent Classification:

C07D 207/267 (2006.01) A61K 31/4439 (2006.01)
C07C 237/52 (2006.01) A61K 31/165 (2006.01)
C07D 401/12 (2006.01) A61K 38/00 (2006.01)
A61P 31/14 (2006.01) C07K 5/02 (2006.01)
A61K 31/4015 (2006.01)

(21) International Application Number:

PCT/GB2021/053374

(22) International Filing Date:

20 December 2021 (20.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020190.1 18 December 2020 (18.12.2020) GB
2107385.3 24 May 2021 (24.05.2021) GB

(71) Applicant: **HEPTARES THERAPEUTICS LIMITED**
[GB/GB]; Granta Park, Great Abington, Cambridge Cam-
bridgeshire CB21 6DG (GB).

(72) Inventors: **CONGREVE, Miles Stuart**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **CHRISTO-
PHER, John Andrew**; c/o Heptares Therapeutics Limited,
Granta Park, Great Abington, Cambridge Cambridgeshire
CB21 6DG (GB). **PICKWORTH, Mark**; c/o Heptares
Therapeutics Limited, Granta Park, Great Abington, Cam-
bridge Cambridgeshire CB21 6DG (GB). **DE GRAAF,
Chris**; c/o Heptares Therapeutics Limited, Granta Park,
Great Abington, Cambridge Cambridgeshire CB21 6DG
(GB). **HIGUERUELO, Alicia Perez**; c/o Heptares Thera-
peutics Limited, Granta Park, Great Abington, Cambridge
Cambridgeshire CB21 6DG (GB). **MASON, Jonathan
Stephen**; c/o Heptares Therapeutics Limited, Granta Park,
Great Abington, Cambridge Cambridgeshire CB21 6DG
(GB). **KULKARNI, Santosh S.**; c/o Syngene Internation-
al Ltd, Biocon Park, SEZ, Bommasandra Industrial Area -
Phase-IV, Jigani Link Road Bangalore 560 099 (IN).

(74) Agent: **STRATAGEM IPM LIMITED**; Meridian Court,
Comberton Road, Toft, Cambridge CB23 2RY (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SARS-COV-2 MPRO INHIBITOR COMPOUNDS



(1')

(57) Abstract: P33613WO1 93 ABSTRACT The disclosures herein relate to compounds of Formula (1'): or a salt thereof, wherein A, Q, X, Z, L, R2, R3 and R9 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro.

WO 2022/129953 A1